Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Michael Goggins

Michael Gilbert Goggins, MD

Associate Professor of Pathology
Professor of Pathology
Male
Appointment Phone

410-933-7495

Primary Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Professor of Pathology
  • Professor of Pathology
  • Professor of Medicine
  • Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Abdominal Pain, Bloating, Burping, Belching, Cancer, Celiac Disease, Chest Pain, Clinical Gastroenterology, Colon Polyps, Constipation, Diarrhea, Digestive Diseases, Diverticulitis, Eosinophilic Esophagitis, Gallbladder, Gallstones, Gas, Gastroenterology, Heartburn, Hiccups, Hoarseness, Indigestion, Irritable Bowel Syndrome, Malabsorption, Nausea, Pancreatic Cancer, Rectal Bleeding, Rectal Problem, Reflux and Burning, Stomach Pain, Stomach Ulcer, Swallowing Disorders, Vomiting, Weight Loss

Biography

Identifying and developing diagnostic markers of pancreatic adenocarcinoma for pancreatic screening. We have evaluated numerous markers for their potential diagnostic utility including blood-based and pancreatic fluid-based markers. Among the studies we have reported include finding that we can reliably identify mutant GNAS genes in pancreatic juice samples from patients with precancerous pancreatic cysts known as IPMNs (intraductal papillary mucinous neoplasm)(1). Similarly, we have shown that we can identify KRAS and TP53 gene mutations in pancreatic juice samples obtained from patients with pancreatic cancer, pancreatic cysts, and those PanIN lesions (2). For example, we found mutations in the TP53 gene were highly specific for the presence of advanced pancreatic neoplasia (mutations were only detected in patients who had either a pancreatic cancer, or an advanced IPMN or PanIN [lesions with moderate to high grade dysplasia]) (2). We can identify these mutations using a variety of technologies including pyrosequencing and next-generation sequencing. Many of the patients enrolled into these studies were undergoing pancreatic screening.

The Cancer of the Pancreas Screening (CAPS) Program: The CAPS program began in 1999 and there have been 5 CAPS studies. Dr. Goggins is PI of the CAPS5 study (clinicaltrials.gov NCT02000089) and works with co-PI, Dr. Marcia Canto to evaluate the utility of screening individuals with multiple first-degree relatives with pancreatic cancer and those with inherited mutations in pancreatic cancer susceptibility genes. CAPS5 is a multi-center trial and involves investigators from muitiple centers including U Pennsylvania, Pittsburgh, Dana Farber, Columbia, Case Western and Yale.

Oncology Clinical Trials:

Phase 1 Clinical trial: Olaparib with irinotecan, cisplatin for patients with advanced pancreatic cancer (Clinicaltrials.gov NCT01296763)(enrollment completed)

Participation in the Pacgene, Panc4 and Panscan consortia: The goal of these studies is to identify inherited gene alterations that increase the risk of developing pancreatic cancer and to use this information to better inform families of their pancreatic cancer risk, the potential need for screening, and how to improve treatments.

Languages

  • English

Additional Resources

Additional Resources +
  • Education +

    Training

    • University of Dublin Trinity College ( Dublin 2) (1988)

    Residencies

    • St James's Hospital ( Dublin 8) (1989)
    • St James's Hospital/Medicine ( Dublin 8) (1991)

    Fellowships

    • Johns Hopkins University School of Medicine ( Baltimore MD ) (1998)
    • St James's Hospital/Internal Medicine ( Dublin 8) (1995)
  • Research & Publications +

    Selected Publications

    Canto, M.I.; Goggins, M.; Hruban, R.H.; Petersen, G.M.; Giardiello, F.M.; Yeo, C.; Fishman, E.K.; Brune, K.; Axilbund, J.; Griffin, C.; Ali, S.; Richman, J.; Jagannath, S.; Kantsevoy, S.V.; Kalloo, A.N. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-781; quiz 665.

    Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-1806.

    Axilbund, J.E.; Argani, P.; Kamiyama, M.; Palmisano, E.; Raben, M.; Borges, M.; Brune, K.A.; Goggins, M.; Hruban, R.H.; Klein, A.P. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009 Jan;8(2):131-135.

    Blackford, A.; Parmigiani, G.; Kensler, T.W.; Wolfgang, C.; Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Eshleman, J.R.; Goggins, M.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Klein, A.; Cameron, J.L.; Olino, K.; Schulick, R.; Winter, J.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W.; Hruban, R.H. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009 Apr 15;69(8):3681-3688.

    Blackford, A.; Serrano, O.K.; Wolfgang, C.L.; Parmigiani, G.; Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Eshleman, J.R.; Goggins, M.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Cameron, J.L.; Olino, K.; Schulick, R.; Winter, J.; Herman, J.M.; Laheru, D.; Klein, A.P.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E.; Hruban, R.H. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009 Jul 15;15(14):4674-4679.

    Jones, S.; Hruban, R.H.; Kamiyama, M.; Borges, M.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Palmisano, E.; Brune, K.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Parmigiani, G.; Kern, S.E.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Eshleman, J.R.; Goggins, M.; Klein, A.P. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009 Apr 10;324(5924):217.

    Koorstra, J.B.; Hong, S.M.; Shi, C.; Meeker, A.K.; Ryu, J.K.; Offerhaus, G.J.; Goggins, M.G.; Hruban, R.H.; Maitra, A. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Mod Pathol. 2009 Nov;22(11):1439-1445.

    Shi, C.; Chandrasekaran, A.; Thuluvath, P.J.; Karikari, C.; Argani, P.; Goggins, M.; Maitra, A.; Eshleman, J.R. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. J Mol Diagn. 2009 Nov;11(6):583-589.

    Wang, L.; Brune, K.A.; Visvanathan, K.; Laheru, D.; Herman, J.; Wolfgang, C.; Schulick, R.; Cameron, J.L.; Goggins, M.; Hruban, R.H.; Klein, A.P. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2829-2834.

    Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N.A.; Hong, S.M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M.G.; Rudek, M.A.; Ravi, R.; Maitra, A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther. 2010 Aug;9(8):2255-2264.

    Brune, K.A.; Lau, B.; Palmisano, E.; Canto, M.; Goggins, M.G.; Hruban, R.H.; Klein, A.P. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010 Jan 20;102(2):119-126.

    De Jong, M.C.; Hong, S.M.; Augustine, M.M.; Goggins, M.; Wolfgang, C.L.; Hirose, K.; Schulick, R.; Choi, M.; Anders, R.; Pawlik, T.M. Proximal cholangiocarcinoma: Tumor Depth Predicts Outcome. Arch Surg. 2010;In Press.

    Feldmann, G.; Mishra, A.; Hong, S.M.; Bisht, S.; Strock, C.J.; Ball, D.W.; Goggins, M.; Maitra, A.; Nelkin, B.D. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010 Jun 1;70(11):4460-4469.

    Gold, D.V.; Goggins, M.; Modrak, D.E.; Newsome, G.; Liu, M.; Shi, C.; Hruban, R.H.; Goldenberg, D.M. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-2794.

    Gurel, B.; Ali, T.Z.; Montgomery, E.A.; Begum, S.; Hicks, J.; Goggins, M.; Eberhart, C.G.; Clark, D.P.; Bieberich, C.J.; Epstein, J.I.; De Marzo, A.M. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010 Aug;34(8):1097-1105.

    Harinck, F.; Canto, M.I.; Schulick, R.; Goggins, M.; Poley, J.W.; Fockens, P.; Kluijt, I.; Bruno, M. Surveillance in individuals at high risk of pancreatic cancer: too early to tell? Gut. 2010 Jul;59(7):1005; author reply 1006-1007.

    Hong, S.M.; Heaphy, C.M.; Shi, C.; Eo, S.H.; Cho, H.; Meeker, A.K.; Eshleman, J.R.; Hruban, R.H.; Goggins, M. Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Mod Pathol. 2010 Sep 24.
    Hruban, R.H.; Canto, M.I.; Goggins, M.; Schulick, R.; Klein, A.P. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311.

    Kamiyama, H.; Kamiyama, M.; Hong, S.M.; Karikari, C.A.; Lin, M.T.; Borges, M.W.; Griffith, M.; Young, A.; Norris-Kirby, A.; Lubek, C.; Mizuma, M.; Feldmann, G.; Shi, C.; Liang, H.; Goggins, M.G.; Maitra, A.; Hruban, R.H.; Eshleman, J.R. In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Lab Invest. 2010 May;90(5):665-673.

    Lennon, A.M.; Klein, A.P.; Goggins, M. ABO blood group and other genetic variants associated with pancreatic cancer. Genome Med. 2010;2(6):39.

    Omura, N.; Griffith, M.; Vincent, A.; Li, A.; Hong, S.M.; Walter, K.; Borges, M.; Goggins, M. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol Cancer Res. 2010 Jun;8(6):821-832.

    Park, J.Y.; S-M., H.; Klimstra, D.S.; Goggins, M.G.; Maitra, A.; Hruban, R.H. Pdx1 Expression in Pancreatic Precursor Lesions and Neoplasms. Applied Immunohistochemistry & Molecular Morphology. 2010;In Press.

    Petersen, G.M.; Amundadottir, L.; Fuchs, C.S.; Kraft, P.; Stolzenberg-Solomon, R.Z.; Jacobs, K.B.; Arslan, A.A.; Bueno-de-Mesquita, H.B.; Gallinger, S.; Gross, M.; Helzlsouer, K.; Holly, E.A.; Jacobs, E.J.; Klein, A.P.; LaCroix, A.; Li, D.; Mandelson, M.T.; Olson, S.H.; Risch, H.A.; Zheng, W.; Albanes, D.; Bamlet, W.R.; Berg, C.D.; Boutron-Ruault, M.C.; Buring, J.E.; Bracci, P.M.; Canzian, F.; Clipp, S.; Cotterchio, M.; de Andrade, M.; Duell, E.J.; Gaziano, J.M.; Giovannucci, E.L.; Goggins, M.; Hallmans, G.; Hankinson, S.E.; Hassan, M.; Howard, B.; Hunter, D.J.; Hutchinson, A.; Jenab, M.; Kaaks, R.; Kooperberg, C.; Krogh, V.; Kurtz, R.C.; Lynch, S.M.; McWilliams, R.R.; Mendelsohn, J.B.; Michaud, D.S.; Parikh, H.; Patel, A.V.; Peeters, P.H.; Rajkovic, A.; Riboli, E.; Rodriguez, L.; Seminara, D.; Shu, X.O.; Thomas, G.; Tjonneland, A.; Tobias, G.S.; Trichopoulos, D.; Van Den Eeden, S.K.; Virtamo, J.; Wactawski-Wende, J.; Wang, Z.; Wolpin, B.M.; Yu, H.; Yu, K.; Zeleniuch-Jacquotte, A.; Fraumeni, J.F., Jr.; Hoover, R.N.; Hartge, P.; Chanock, S.J. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010 Mar;42(3):224-228.

    Rasheed, Z.A.; Yang, J.; Wang, Q.; Kowalski, J.; Freed, I.; Murter, C.; Hong, S.M.; Koorstra, J.B.; Rajeshkumar, N.V.; He, X.; Goggins, M.; Iacobuzio-Donahue, C.; Berman, D.M.; Laheru, D.; Jimeno, A.; Hidalgo, M.; Maitra, A.; Matsui, W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010 Mar 3;102(5):340-351.

    Ryu, J.K.; Hong, S.M.; Karikari, C.A.; Hruban, R.H.; Goggins, M.G.; Maitra, A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10(1):66-73.
  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Upcoming Events +
  • Contact & Locations +

    Locations

    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Sheikh Zayed Tower
    Baltimore, MD 21287
    Appointment Phone: 410-933-7495
    Location Map
    Johns Hopkins Community Physicians - Green Spring Station
    2360 W. Joppa Road
    Joppa Concourse
    Lutherville, MD 21093
    Appointment Phone: 410-616-7350
    Location Map
    Johns Hopkins Medicine - Green Spring Station
    10755 Falls Road
    Pavilion I
    Lutherville, MD 21093
    Appointment Phone: 410-583-2888
    Location Map

    Department/Division

    • Medicine - Gastroenterology and Hepatology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer